An effective probiotic that can fight Listeria monocytogenes bacteria



    LAVAL, QC, Aug. 29 /CNW Telbec/ - In the wake of the food crisis
currently hitting Canada, biotechnology company Bio-K+ International Inc.
believes that it is important to go public with the results of an in vitro
study(1) conducted in 2005 by researchers at the INRS-Institut
Armand-Frappier. The study, which was published in 2007 in Letters in Applied
Microbiology, a peer review journal, demonstrates the effectiveness of Bio-K+
CL1285(R) in inhibiting the growth of certain pathogenic bacteria, including
Listeria monocytogenes.
    The in vitro experiment conducted by Dr. Mathieu Millette, under the
direction of Dr. Monique Lacroix, Professor and Researcher at the
INRS-Institut Armand-Frappier, demonstrated that the Bio-K+ CL1285(R) formula
reduced the development of several pathogenic bacteria, including Listeria
monocytogenes, in a proportion of 78.4% after a 12-hour incubation. It should
be noted that the experiment was conducted with the same formula as the fresh
product available in stores and in the same concentration, which is 50 billion
friendly bacteria.
    According to Mr. Claude Chevalier, the company's President and CEO : "it
goes without saying that this study constitutes a significant indicator of
Bio-K+CL1285(R)'s ability to act on pathogenic bacteria. Although further
study is required to understand the full extent of the product's effectiveness
in the human body, we think it is crucial that Canadians be aware right now of
the results obtained in vitro, because they demonstrate that the product
reduces the growth of the pathogenic bacterium, Listeria monocytogenes."
    This in vitro research is even more relevant in view of the randomized
double-blind study conducted at the Maisonneuve-Rosemont Hospital in 2004 that
was recently published in the Canadian Journal of Gastroenterology.(2) This
study concluded that Bio-K+ CL1285(R) was effective in preventing the
antibiotic-associated diarrhea (AAD) in patients in a hospital setting. Other
randomized double-blind studies are currently underway to treat patients
suffering from traveller's diarrhea, which is often associated to food
poisoning, and from AAD in several hospitals as well as from Clostridium
difficile.

    About Bio-K+ International Inc.

    Founded in 1994, Bio-K+ International Inc. is a Quebec-based family
biotechnology business that specializes in the production, marketing and
distribution of 100% probiotic products. The company, which is headquartered
in Laval's Science and High Technology Park, has more than 80 employees in
Canada and the United States, and distributes its products in natural food
stores, pharmacies and supermarkets across North America. For more
information, please visit www.biokplus.com.

    
    ------------------------
    (1) Millette, M., F.M. Luquet, M. Lacroix. 2007. In vitro growth control
    of selected pathogens by Lactobacillus acidophilus and Lactobacillus
    casei-fermented milk, Letters in Applied Microbiology, Vol. 44. P.
    314-319. Available at www.biokplus.ca

    (2) Beausoleil, M., N. Fortier, S. Guénette, A. L'Ecuyer, M. Savoie,
    M. Franco, J. Lachaîne, K. Weiss. 2007. Effect of a fermented milk
    combining Lactobacillus acidophilus CL1285 and Lactobacillus casei in the
    prevention of antibiotic-associated diarrhea : A randomized, double-
    blind, placebo-controlled trial. Canadian Journal of Gastroenterology,
    Vol. 21. P. 732-736. Available at www.biokplus.ca
    




For further information:

For further information: Catherine Escojido, (514) 927-8807; Source:
Bio-K + International inc.

Organization Profile

Bio-K+ International Inc.

More on this organization

LISTERIA OUTBREAK

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890